These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 21299928)

  • 1. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.
    Edholm T; Degerblad M; Grybäck P; Hilsted L; Holst JJ; Jacobsson H; Efendic S; Schmidt PT; Hellström PM
    Neurogastroenterol Motil; 2010 Nov; 22(11):1191-200, e315. PubMed ID: 20584260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapancreatic effects of GIP and GLP-1.
    Vella A; Rizza RA
    Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of incretin hormones to the pathogenesis of type 2 diabetes.
    Meier JJ
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):433-41. PubMed ID: 19748061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
    Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
    Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the physiology of GIP and GLP-1.
    Holst JJ
    Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.
    Hellström PM
    Vitam Horm; 2010; 84():319-29. PubMed ID: 21094906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
    Toft-Nielsen M; Madsbad S; Holst JJ
    Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.